SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a leading genetic cause of death in children, caused by the loss of the SMN1 gene.
• The SMN2 gene produces insufficient amounts of functional SMN protein due to inefficient splicing.

Purpose of the Study:

• To develop and characterize a novel small molecule that enhances SMN2 gene splicing.
• To investigate the therapeutic potential of this molecule in a severe SMA mouse model.

Main Methods:

• Administration of an orally active small-molecule SMN2 splicing enhancer to a severe SMA mouse model.
• Assessment of full-length SMN protein levels and survival rates.
• Elucidation of the molecular mechanism of action through analysis of RNA structures and protein interactions.

Main Results:

• The small molecule significantly increased full-length SMN protein levels.
• Oral administration of the compound extended survival in the SMA mouse model.
• The drug functions by stabilizing the SMN2 pre-mRNA and U1 snRNP complex, enhancing sequence-selective splice site recognition.

Conclusions:

• Small molecule-mediated, sequence-selective modulation of SMN2 splicing is feasible.
• This approach offers a promising therapeutic strategy for SMA and potentially other splicing-related genetic disorders.